WO2008063092A2 - Microstructural protein preparations containing adsorbed biologically active substances and their application in medicine and cosmetics - Google Patents
Microstructural protein preparations containing adsorbed biologically active substances and their application in medicine and cosmetics Download PDFInfo
- Publication number
- WO2008063092A2 WO2008063092A2 PCT/PL2007/000078 PL2007000078W WO2008063092A2 WO 2008063092 A2 WO2008063092 A2 WO 2008063092A2 PL 2007000078 W PL2007000078 W PL 2007000078W WO 2008063092 A2 WO2008063092 A2 WO 2008063092A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- biologically active
- protein preparations
- preparations containing
- active compounds
- containing biologically
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Definitions
- Novel microstructural protein preparations containing adsorbed biologically active substances and their application in medicine and cosmetics are novel microstructural protein preparations containing adsorbed biologically active substances and their application in medicine and cosmetics
- the subject of the present invention are novel microstructural protein preparations containing adsorbed biologically active substances and their application in medicine and cosmetics.
- the traditional administration of an active substance in medicine or cosmetics such as intramuscular or intravenous, or as oral capsules or as lotions or creams containing the active substance are generally characterized by a rapid but short-lived increase of the concentration of the active substance.
- Conglomerates of the active substance and and a high-molecular mass substance are used to prolong its release period. Such compounds release the active substance by way of diffusion and/or degradation of the high molecular mass compound.
- Bozenna Baranowska, Andrzej lipkowski, Ewa Marczak, Irrnina Makulec, Hanna Rybak, Joanna Pastuszak, Anna Szulc, Aleksandra Szczuci ⁇ ska, Wieslawa Wasilewicz-Niedbalska, and Zofia Grabska have patented "A method of obtaining art abrasive agent for chaining and exfoliating skin", Polish Patent PL 179302, for obtaining protein preparations for use as an exfoliant in cosmetics.
- the method of obtaining the preparation according to said patent description consisted of the enzymatic digestion of natural structural protein sources, including hair, bristles, wool or feathers and then grinding the remaining solids to a protein preparation of predetermined particle size.
- the goal of the present invention is to propose the production of new protein preparations, where active substances are adsorbed onto the highly developed surface and into micropores, which facilitate the application of said preparations as the active substance in medicinal compounds or cosmetics.
- this goal has been realized in the present invention.
- biologically active substances such as high- molecular mass proteins and peptides or lipophylic low-molecular mass compounds effectively adsorb onto the highly developed surfaces and micropores of protein preparations.
- These new microstructural protein preparations can constitute the active component in medicinal or cosmetic preparations with active substances adsorbed onto them. Following application, the active substance is slowly released from the protein preparation.
- Example III 50 g of dry SSP-2 obtained as in Example I was supplemented with 100 ml ethyl acetate extract from green tea. The SSP-2 suspension was mixed intensively for 20 minutes at 3O 0 C, and then drained, and the filtrate was washed twice in ethanol. Following drying, 55 g of SSP-2 with suspended green tea polyphenols were obtained. After drying, the preparation was added to a skin regenerating cream.
- Example IV 5 g of dry SSP-2 obtained as in Example I were supplemented with 20 ml of a 20% colchicine solution in 10% ethanol. The SSP-2 suspension was mixed intensively for 20 minutes at 3O 0 C, drained, and the filtrate was washed twice in water. After drying, 55 g of SSP-2 were obtained for use in creams for treating inflammation.
- Example IV 5 g of dry SSP-2 obtained as in Example I were supplemented with 20 ml of a 20% colchicine solution in 10% ethanol. The SSP-2 suspension was mixed intensively for 20 minutes at 3O 0 C, drained, and the filtrate was washed twice in water. After drying, 55 g of SSP-2 were obtained for use in creams for treating inflammation.
- Example IV 5 g of dry SSP-2 obtained as in Example I were supplemented with 20 ml of a 20% colchicine solution in 10% ethanol. The SSP-2 suspension was mixed intensively for 20 minutes at 3O 0 C, drained, and the filtrate
- the suspension was mixed for 2 hours at 35 0 C, drained, washed thrice in water and dried.
- the dry preparation was ground again and sieved, collecting product less than 0.25 mm long.
- the preparation obtained was suspended in 1% lye, and then centrifuged after 1 h, washed in water, recentrifuged, washed in 1% HCl and centrifuged again. The remainder was suspended in water, the suspension was acidified to 2,2 and pepsin was added.
- the suspension was mixed for 2 h at 35 0 C, centrifuged and the insoluble portion was washed by suspending it in water, and then dried. 25 g of scaffolding protein material was obtained from human hair, designated as HSP-2.
- Example V 0.5 g of dry and sterile HSP-2 were supplemented with 2 mg of fibronectin from human serum suspended in 2 ml of sterile water. The aqueous solution completely adsorbed onto HSP-2. The product was washed in 50% ethanol and dried in a desiccators under reduced pressure. After drying, the product was used as a component of a medium used for in a culturing human skin tissue.
- Example V
- Example IV 5 g of dry HSP-2 obtained as in Example IV, were supplemented under sterile conditions with 10 ml of an aqueous solution of the opioid peptide morphoceptin and the antibiotic penicillin. After the solution was absorbed, the preparation was dired. The product was used as a wound powder for difficult-to-heal diabetic lesions. Wound closure and healing were observed.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Protein preparations containing biologically active compounds and the application of the protein preparations obtained, particularly as a component of medicinal and cosmetic preparations as protective substances or in the regeneration of cells and tissues of the human organism, and which can comprise a component of culture media for dermal or hepatic tissues, or for stem cells destined for use in the regeneration of cells and tissues in the human organism.
Description
Novel microstructural protein preparations containing adsorbed biologically active substances and their application in medicine and cosmetics
The subject of the present invention are novel microstructural protein preparations containing adsorbed biologically active substances and their application in medicine and cosmetics.
The traditional administration of an active substance in medicine or cosmetics, such as intramuscular or intravenous, or as oral capsules or as lotions or creams containing the active substance are generally characterized by a rapid but short-lived increase of the concentration of the active substance. Conglomerates of the active substance and and a high-molecular mass substance are used to prolong its release period. Such compounds release the active substance by way of diffusion and/or degradation of the high molecular mass compound.
Bozenna Baranowska, Andrzej lipkowski, Ewa Marczak, Irrnina Makulec, Hanna Rybak, Joanna Pastuszak, Anna Szulc, Aleksandra Szczuciήska, Wieslawa Wasilewicz-Niedbalska, and Zofia Grabska have patented "A method of obtaining art abrasive agent for chaining and exfoliating skin", Polish Patent PL 179302, for obtaining protein preparations for use as an exfoliant in cosmetics. The method of obtaining the preparation according to said patent description consisted of the enzymatic digestion of natural structural protein sources, including hair, bristles, wool or feathers and then grinding the remaining solids to a protein preparation of predetermined particle size. Research showed that cosmetics containing
protein preparations according to said patent were not allergenic when used as an exfoliant in cream. A modification of the manufacturing process was proposed as a result of further research which consisted of repeated enzymatic digestion of the source material. This process was described in the Polish patent application by Andrzej W. Lipkowski, Marcin Jurga, Krystyna Domaήska-Janik, Barbara Lukomska, entitled "New protein skeleton preparations, their production and applications", P380011 and leads to the production of a protein preparation, which may be applied in animals, humans and in stem cell cultures. Further structural research of the material produced showed that it has a microporous structure. The goal of the present invention is to propose the production of new protein preparations, where active substances are adsorbed onto the highly developed surface and into micropores, which facilitate the application of said preparations as the active substance in medicinal compounds or cosmetics. Unexpectedly, this goal has been realized in the present invention. Unexpectedly, it has been shown that biologically active substances such as high- molecular mass proteins and peptides or lipophylic low-molecular mass compounds effectively adsorb onto the highly developed surfaces and micropores of protein preparations. These new microstructural protein preparations can constitute the active component in medicinal or cosmetic preparations with active substances adsorbed onto them. Following application, the active substance is slowly released from the protein preparation. Due to this, one obtains the complementary activity of the protein preparation as a skeletal structural material and long-term active substance activity which acts at the application site. As a result, new protein preparations with adsorbed active substances can be used in medicine and cosmetics, particularly in such cases as wound treatment, skin protection, post-surgical lesion repair, and in vitro cell and tissue cultures.
To better illustrate the present invention, novel scaffolding protein preparations and the method of obtaining novel scaffolding protein preparations, and the application of said preparations in stem cell cultures. The scope of the present invention should not be limited to the contents of the examples below. Example I
1 kg of sheep's wool was placed in 1% lye and mixed for 1 hour at room temperature. The lye was then drained off and the wool was washed twice in water and suspended in water. The suspension was acidified with hydrochloric acid to pH 2.2 and pepsin was added. The mixture was agitated for 3 hours at 350C, and then the wool solids were drained off, washed twice in water and sieved to collect particles of less than 1 mm in length. The preparation produced was innundated with 1% lye and then drained after 1 h, washed in water and then in 1% hydrochloric acid and drained. The remainder was suspended in water, acidified to pH 2.2 and pepsin was added. The suspension was mixed for 2 h at 350C, then drained, washed three times in water and dried. 500 g of scaffolding protein material from sheep's wool was obtained, and was designated SSP-2.
100 g of Dry SSP-2 was placed in 1000 ml of Merlot wine. The suspension of SSP-2 in wine was mixed for 20 minutes at 3O0C, and then drained off. The precipitate was washed three times under water. After drying, 105 g of SSP-2 with adsorbed wine polyphenols were obtained. Following drying, the preparation was added to regenerating skin cream. Example II
50 g of dry SSP-2 obtained as in Example I was supplemented with 100 ml ethyl acetate extract from green tea. The SSP-2 suspension was mixed intensively for 20 minutes at 3O0C, and then drained, and the filtrate was washed twice in ethanol. Following drying, 55 g of SSP-2 with suspended green tea polyphenols were obtained. After drying, the preparation was added to a skin regenerating cream.
Example III
5 g of dry SSP-2 obtained as in Example I were supplemented with 20 ml of a 20% colchicine solution in 10% ethanol. The SSP-2 suspension was mixed intensively for 20 minutes at 3O0C, drained, and the filtrate was washed twice in water. After drying, 55 g of SSP-2 were obtained for use in creams for treating inflammation. Example IV
100 g of human hair were inundated with 1% lye and mixed for 1 hour at RT. The lye was drained off and the hair was washed twice in water and suspended in water. The suspension was acidified with HCl to pH 2.2 and pepsin was added. The mixture was agitated for 3 hours at 350C, and then the hair solids were drained off, washed twice in water and dried. The dry preparation was ground and sieved, collecting product smaller than 1 mm in length . The preparation obtained was suspended in 1% lye, and then centrifuged after 1 h, washed in 1% HCl and recentrifuged. The remainder was suspended in water, the suspension was acidified to pH 2.2 and pepsin was added. The suspension was mixed for 2 hours at 350C, drained, washed thrice in water and dried. The dry preparation was ground again and sieved, collecting product less than 0.25 mm long. The preparation obtained was suspended in 1% lye, and then centrifuged after 1 h, washed in water, recentrifuged, washed in 1% HCl and centrifuged again. The remainder was suspended in water, the suspension was acidified to 2,2 and pepsin was added. The suspension was mixed for 2 h at 350C, centrifuged and the insoluble portion was washed by suspending it in water, and then dried. 25 g of scaffolding protein material was obtained from human hair, designated as HSP-2.
0.5 g of dry and sterile HSP-2 were supplemented with 2 mg of fibronectin from human serum suspended in 2 ml of sterile water. The aqueous solution completely adsorbed onto HSP-2. The product was washed in 50% ethanol and dried in a desiccators under reduced
pressure. After drying, the product was used as a component of a medium used for in a culturing human skin tissue. Example V
5 g of dry HSP-2 obtained as in Example IV, were supplemented under sterile conditions with 10 ml of an aqueous solution of the opioid peptide morphoceptin and the antibiotic penicillin. After the solution was absorbed, the preparation was dired. The product was used as a wound powder for difficult-to-heal diabetic lesions. Wound closure and healing were observed.
Claims
1. Novel protein preparations containing biologically active compounds, characterised in that the scaffolding protein preparations obtained from products of animal vertebrate epithelia, particularly of birds and mammals, mostly devoid of soluble proteins constitute a carrier for adsorbed active substances.
2. Novel protein preparations containing biologically active compounds according to Claim 1, characterised in that the adsorption of active substances onto the previously obtained protein preparation is carried out by the mixing of the protein preparation in an aqueous solution of the active substance and then drying.
3. Novel protein preparations containing biologically active compounds according to Claim 1, characterised in that the adsorption of active substances onto a previously obtained protein preparation is carried out by mixing the protein preparation in a polar organic solvent such as dimethylformaminde, ethanol, methanol, methyl acetate, ethyl acetate, dioxane, acetic acid, dimethylsulfoxide or a mixture of these solvents containing a dissolved active substance, and thence drying the preparation thus obtained.
4. Novel protein preparations containing biologically active compounds according to Claims 1, 2 and 3, characterised in that the active substances are biologically active natural plant extracts or their derivatives, including grape extract or red wine or green tea extract or colchicine or silmarine.
5. Novel protein preparations containing biologically active compounds according to Claims 1, 2 and 3, characterised in that the active substances are biologically active proteins or peptides including growth hormone or its active fragments or analogues, neuronal growth factor or its active fragments, fibronectin or its active fragments, hemocyte growth factor, tachykinins or their active analogues, or opioid peptides.
6. Novel protein preparations containing biologically active compounds according to Claims 1, 2 and 3, characterised in that the active substances are synthetic medicaments, including anti-inflammatory substances, including acetylsalicylic acid and ibuprofen, diclofenac and/or analgesic substances, including fentanyl or morphine and/or antibacterial substances, including beta-lactamic antibiotics.
7. Novel protein preparations containing biologically active compounds according to Claims 1, 2, 3, 4, 5 and 7, characterised in that the nov el protein preparations containing biologically active compounds comprise a component of creams used in the treatment of wounds or local inflammations or local bacterial or viral infections, or are a component of regenerative or sunscreen creams used as cosmetics.
8. Novel protein preparations containing biologically active compounds according to Claims 1, 2, 3, 4, 5 and 7, characterised in that the novel protein preparations containing biologically active compounds comprise components of subdermal implants used in the treatment of chronic pain.
9. Novel protein preparations containing biologically active compounds according to Claims 1, 2, 3, 4, 5 and 7, characterised in that the novel protein preparations containing biologically active compounds comprise a component of implants for reconstructing missing tissue and lesions resulting from tumor-removal surgery.
10. Novel protein preparations containing biologically active compounds according to Claims 1, 2, 3, 4, 5 and 7, characterised in that the novel protein preparations containing biologically active compounds comprise a component of culture media for dermal or liver tissue, or stem cells destined for use in the regeneration of cells and tissues in the human.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07834906.5A EP2097066B1 (en) | 2006-11-21 | 2007-11-20 | Microstructural protein preparations containing adsorbed biologically active substances and their application in medicine and cosmetics |
US12/312,576 US8715701B2 (en) | 2006-11-21 | 2007-11-20 | Microstructural protein preparations containing adsorbed biologically active substances and their application in medicine and cosmetics |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PLP381103 | 2006-11-21 | ||
PL381103A PL227142B1 (en) | 2006-11-21 | 2006-11-21 | New microstructured protein preparations with adsorbed biologically active substances as well as their medicinal and cosmetic applications |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008063092A2 true WO2008063092A2 (en) | 2008-05-29 |
WO2008063092A3 WO2008063092A3 (en) | 2009-05-14 |
Family
ID=39048813
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/PL2007/000078 WO2008063092A2 (en) | 2006-11-21 | 2007-11-20 | Microstructural protein preparations containing adsorbed biologically active substances and their application in medicine and cosmetics |
Country Status (4)
Country | Link |
---|---|
US (1) | US8715701B2 (en) |
EP (1) | EP2097066B1 (en) |
PL (2) | PL227142B1 (en) |
WO (1) | WO2008063092A2 (en) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2854381A (en) * | 1955-12-08 | 1958-09-30 | Bristol Myers Co | Resin laxative tablets containing hydrolyzed keratin |
US6544548B1 (en) * | 1999-09-13 | 2003-04-08 | Keraplast Technologies, Ltd. | Keratin-based powders and hydrogel for pharmaceutical applications |
WO2003064449A2 (en) * | 2002-01-28 | 2003-08-07 | Keraplast Technologies, Ltd. | Bioactive keratin peptides |
WO2004047774A1 (en) * | 2002-11-28 | 2004-06-10 | Keratec Limited | Personal care formulations containing keratin |
US20050058686A1 (en) * | 2002-07-25 | 2005-03-17 | Mark Van Dyke | Bioactive coating for medical devices |
US20050232875A1 (en) * | 2002-07-25 | 2005-10-20 | Umeda Jimusho Ltd. | Water-soluble keratin derivative and use thereof |
WO2007050387A2 (en) * | 2005-10-21 | 2007-05-03 | Wake Forest University Health Sciences | Keratin bioceramic compositions |
EP1815843A2 (en) * | 2005-12-29 | 2007-08-08 | Henkel KGaA | Synergistic protein hydrolysate combinations for treating mature skin |
EP1878423A2 (en) * | 2006-07-13 | 2008-01-16 | Beiersdorf AG | Hair styling preparations with special protein hydrolysates |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5058686A (en) * | 1986-10-27 | 1991-10-22 | Mickey Redwine | Sliding-weight operated hole boring tool |
US5232875A (en) * | 1992-10-15 | 1993-08-03 | Micron Technology, Inc. | Method and apparatus for improving planarity of chemical-mechanical planarization operations |
JP3231013B2 (en) * | 1997-12-04 | 2001-11-19 | 一丸ファルコス株式会社 | Manufacturing method of antibacterial processed fiber |
JP3430257B2 (en) * | 2000-08-30 | 2003-07-28 | 独立行政法人農業生物資源研究所 | Hazardous substance adsorption material and toxic substance desorption method |
JP2006078227A (en) * | 2004-09-07 | 2006-03-23 | Shinshu Univ | Protein colloid aqueous solution and model blood including it |
-
2006
- 2006-11-21 PL PL381103A patent/PL227142B1/en unknown
-
2007
- 2007-11-20 EP EP07834906.5A patent/EP2097066B1/en not_active Not-in-force
- 2007-11-20 PL PL07834906T patent/PL2097066T3/en unknown
- 2007-11-20 US US12/312,576 patent/US8715701B2/en not_active Expired - Fee Related
- 2007-11-20 WO PCT/PL2007/000078 patent/WO2008063092A2/en active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2854381A (en) * | 1955-12-08 | 1958-09-30 | Bristol Myers Co | Resin laxative tablets containing hydrolyzed keratin |
US6544548B1 (en) * | 1999-09-13 | 2003-04-08 | Keraplast Technologies, Ltd. | Keratin-based powders and hydrogel for pharmaceutical applications |
WO2003064449A2 (en) * | 2002-01-28 | 2003-08-07 | Keraplast Technologies, Ltd. | Bioactive keratin peptides |
US20050058686A1 (en) * | 2002-07-25 | 2005-03-17 | Mark Van Dyke | Bioactive coating for medical devices |
US20050232875A1 (en) * | 2002-07-25 | 2005-10-20 | Umeda Jimusho Ltd. | Water-soluble keratin derivative and use thereof |
WO2004047774A1 (en) * | 2002-11-28 | 2004-06-10 | Keratec Limited | Personal care formulations containing keratin |
WO2007050387A2 (en) * | 2005-10-21 | 2007-05-03 | Wake Forest University Health Sciences | Keratin bioceramic compositions |
EP1815843A2 (en) * | 2005-12-29 | 2007-08-08 | Henkel KGaA | Synergistic protein hydrolysate combinations for treating mature skin |
EP1878423A2 (en) * | 2006-07-13 | 2008-01-16 | Beiersdorf AG | Hair styling preparations with special protein hydrolysates |
Non-Patent Citations (5)
Title |
---|
DATABASE CA CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002518854 retrieved from STN Database accession no. 144:288969 & JP 2006 078227 A (SHINSHU UNIVERSITY) 23 March 2006 (2006-03-23) * |
DATABASE CA CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002518855 retrieved from STN Database accession no. 131: 74917 & JP 11 172578 A (ICHIMARU PHARCOS INC.) 29 June 1999 (1999-06-29) * |
DATABASE CA CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002518856 retrieved from STN Database accession no. 136: 221771 & JP 2002 066315 A (NOGYO SEIBUTSU SHIGEN KENKYUSHO) 5 March 2002 (2002-03-05) * |
F. MERKI ET AL.: "Beziehungen zwischen den physikalisch-chemischen Eigenschaften, der chemischen Reaktivität und der lokalanästhetischen Wirkung. 32. Mitteilung (1. Teil)" ARZNEIMITTEL-FORSCHUNG, vol. 25, no. 7, 1975, pages 997-1004, XP008103664 * |
F. MERKI ET AL.: "Beziehungen zwischen den physikalisch-chemischen Eigenschaften, der chemischen Reaktivität und der lokalanästhetischen Wirkung. 32. Mitteilung (2. Teil)" ARZNEIMITTEL-FORSCHUNG, vol. 25, no. 8, 1975, pages 1233-1240, XP008103667 * |
Also Published As
Publication number | Publication date |
---|---|
EP2097066B1 (en) | 2016-08-10 |
PL2097066T3 (en) | 2017-04-28 |
US20100047196A1 (en) | 2010-02-25 |
US8715701B2 (en) | 2014-05-06 |
PL381103A1 (en) | 2008-05-26 |
WO2008063092A3 (en) | 2009-05-14 |
PL227142B1 (en) | 2017-11-30 |
EP2097066A2 (en) | 2009-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102015764B (en) | Cosmetic or pharmaceutical compositions comprising metalloproteinase inhibitors | |
JP2988876B2 (en) | Hair growth agent | |
JP5911874B2 (en) | Use of exosomes to promote or enhance hair growth | |
US8871716B2 (en) | Use of antimicrobial peptides in regeneration of skin cells | |
JP2001522877A (en) | Prolamin-vegetable polar lipid composite, process for its production and use thereof | |
CN109456389B (en) | Antibacterial peptide, antibacterial peptide hydrogel and preparation method thereof | |
US6979670B1 (en) | Matrix protein compositions for grafting | |
CN110072875A (en) | For treat and/or nursing skin, hair, nail and/or mucous membrane compound | |
US20170112737A1 (en) | Cosmetics and pharmaceutical applications of gallic acid and gallic acid derivatives | |
JP2022513418A (en) | Skin regeneration and healing mixture of peptide components and their use | |
WO2002094256A1 (en) | Lysine and/or analogues and/or polymers thereof for promoting wound healing and angiogenesis | |
JP5342455B2 (en) | Short bioactive peptides for cell and immune regulation | |
EP1165102B1 (en) | Matrix protein compositions for grafting in non-mineralised tissue | |
US8715701B2 (en) | Microstructural protein preparations containing adsorbed biologically active substances and their application in medicine and cosmetics | |
KR101688696B1 (en) | Composition for Wound Healing Comprising Enkephalin Variant | |
DE60008077T2 (en) | Matrix protein compositions to induce apoptosis | |
WO2012046922A1 (en) | Novel use of antimicrobial peptides in regeneration of skin cells | |
KR101444303B1 (en) | Cosmetic composition including hydrolysate from silkworm gland | |
CN114874306B (en) | Egg shell membrane polypeptide composition, preparation method and application thereof in wrinkle resistance and alopecia resistance | |
KR20240052089A (en) | How to Treat Nonbleeding Wounds, Chronic Wounds, Inflammatory Pain, and Nociceptive Pain | |
JPS63152322A (en) | Solution containing fibronectin derived from placenta tissue | |
JPH0662428B2 (en) | Method for producing a preparation for promoting wound healing | |
JP2024030965A (en) | Promoter for fat cell differentiation and fat production for skin and skin care preparation | |
Jabeen et al. | Protective effects of Euphorbia helioscopia on different wound models in rats | |
CN117088941A (en) | Tripeptide derivative, composition and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2007834906 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007834906 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12312576 Country of ref document: US |